Abstract
The ligand-dependent degradation of activated tyrosine kinase receptors provides a means by which mitogenic signalling can be attenuated. In many cell types the ligand-dependent degradation of the tyrosine kinase receptor Met is completely dependent on the activity of the 26S proteasome (Jeffers et al., 1997b). We now show that degradation also requires trafficking to late endosomal compartments and the activity of acid dependent proteases as determined by the effects of a dominant negative form of dynamin (K44A) and a vacuolar-ATPase inhibitor, concanamycin. We show that in the presence of the proteasome inhibitor lactacystin, Met fails to redistribute from the plasma membrane to intracellular compartments. This observation is most consistent with the interpretation that proteasome activity is required for Met internalization and only indirectly for its degradation.
Similar content being viewed by others
References
Bonifacino JS, Weissman A . 1998 Annu. Rev. Cell. Dev. Biol. 14: 19–57
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA . 1991 Science 251: 802–804
Chau V, Tobias JW, Bachmair A, Marriot D, Ecker DJ, Gonda DK, Varshavsky A . 1989 Science 243: 1576–1583
Clague MJ . 1998 Biochem. J. 336: 271–282
Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF . 1984 Nature 311: 29–33
Damke H, Baba T, Warnock DE, Schmid S . 1994 J. Cell Biol. 127: 915–934
Deveraux O, Ustrell V, Pickart C, Rechsteiner M . 1994 J. Biol. Chem. 269: 7059–7061
Di Fiore PP, Gill GN . 1999 Curr. Op. Cell Biol. 11: 483–488
Galcheva-Gargova Z, Theroux SJ, Davis RJ . 1995 Oncogene 11: 2649–2655
Giordano S, Di Renzo MF, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM . 1989 Oncogene 4: 1383–1388
Govers R, ten Broeke T, van Kerkhof P, Schwartz AL, Strous GJ . 1999 EMBO J. 18: 28–36
Govers R, van Kerkhof P, Schwartz AL, Strous GJ . 1997 EMBO J. 16: 4851–4858
Heuser J, Anderson RGW . 1989 J. Cell Biol. 108: 389–400
Hicke L . 1999 Trends in Cell Biol. 9: 107–112
Hou D, Cenciarelli C, Jensen JP, Nguyen HB, Weissman AM . 1994 J. Biol. Chem. 269: 14244–14247
Jeffers M, Rong S, Vande Woude GF . 1996 J. Mol. Med. 74: 505–513
Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF . 1997a Proc. Natl. Acad. Sci. USA 94: 11445–11450
Jeffers M, Taylor GA, Weidner KM, Omura S, Vande Woude GF . 1997b Mol. Cell Biol. 17: 799–808
Kobyashi T, Stang E, Fang KS, de Moerloose P, Parton RG, Gruenberg J . 1998 Nature 392: 193–197
Lefkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y . 1998 Genes Dev. 12: 3663–3674
Miyazawa K, Toyama K, Gotoh A, Hendrie PC, Mantel C, Broxmeyer HE . 1994 Blood 83: 137–145
Mori S, Heldin C-H, Claesson-Welsh L . 1992 J. Biol. Chem. 267: 6429–6434
Mori S, Kanaki H, Tanaka K, Morisaki N, Saito Y . 1995a Biochem. Biophys. Res. Commun. 217: 224–229
Mori S, Tanaka K, Omura S, Saito Y . 1995b J. Biol. Chem. 270: 29447–29452
Mu F-T, Callaghan JM, Steele-Mortimer O, Stenmark H, Parton RG, Campbell PL, McCluskey J, Yeo J-P, Tock EPC, Toh B-H . 1995 J. Biol. Chem. 270: 13503–13511
Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Diakhura H, Tsubouchi H, Blasi F, Comoglio PM . 1992 EMBO J. 11: 4825–4833
Naldini L, Weidner KM, Vigna G, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, Birchmeier W, Comoglio PM . 1991 EMBO J. 10: 2867–2878
Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, Vande Woude GF . 1986 Cell 45: 895–904
Rodrigues GA, Park M . 1993 Mol. Cell Biol. 13: 6711–6722
Rong S, Oskarsson D, Faletto I, Tsarfaty JH, Resau JH, Nakamura T, Rosen E, Hopkins RF, Vande Woude GF . 1993 Cell Growth Differ. 4: 563–594
Rubin JS, Bottaro DP, Aaronson SA . 1993 Biochim. Biophys. Acta 1155: 357–371
Terrel J, Shih S, Dunn R, Hicke L . 1998 Mol. Cell 1: 193–202
van der Bliek A, Redelmeier T, Damke H, Tisdale E, Meyerowitz E, Schmid S . 1993 J. Cell Biol. 122: 553–563
van der Voort R, Taher TEI, Derksen PWB, Spaargaren M, Van de Neut R, Pals ST . 2000 Adv. Cancer Res. 79: 39–90
van Kerkhof P, Govers R, Alves dos Santos CM, Strous GJ . 2000 J. Biol. Chem. 275: 1575–1580
Vieira AV, Lamaze C, Schmid SL . 1996 Science 274: 2086–2089
Wells A, Welsh JB, Lazar CS, Wiley S, Gill GN, Rosenfeld MG . 1990 Science 247: 962–964
Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y . 1991 J. Biol. Chem. 266: 17707–17712
Acknowledgements
Dean Hammond is the recipient of a Wellcome Trust prize studentship. Sylvie Urbé is supported by a fellowship from the North West Cancer Research Fund. We thank members of the Haematology Department, University of Liverpool for allowing us to use their con-focal microscope. We also thank Jean Gruenberg and Harry Mellor for provision of antibodies and Dave Fernig for EGF.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hammond, D., Urbé, S., Vande Woude, G. et al. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20, 2761–2770 (2001). https://doi.org/10.1038/sj.onc.1204475
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204475
- Springer Nature Limited
Keywords
This article is cited by
-
Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET
Journal of Neuro-Oncology (2023)
-
Endosomal LC3C-pathway selectively targets plasma membrane cargo for autophagic degradation
Nature Communications (2022)
-
Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis
Signal Transduction and Targeted Therapy (2021)
-
Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
Scientific Reports (2019)
-
SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma
Cell Death & Disease (2018)